SCHEMBL123883

SCHEMBL123883

Cc1cc(C)c(S(=O)(=O)NO)c(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 1.00
CA2 P00918 2/20 1.00
MMP1 P03956 2/20 1.00
MMP2 P08253 2/20 1.00
MMP9 P14780 2/20 1.00
MMP8 P22894 2/20 1.00
MMP13 P45452 2/20 1.00
F2 P00734 3/20 0.56
PRSS1 P07477 3/20 0.56
PRSS2 P07478 3/20 0.56
PRSS3 P35030 3/20 0.56
POLB P06746 1/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.55
GFER P55789 1/20 0.55
CYTH2 Q99418 1/20 0.51
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL9033021 0.98 CA1 (0.96) CA1CA2MMP1MMP2MMP9
SCHEMBL28191532 0.83 CA1 (0.70) CA1CA2MMP1MMP2MMP9
SCHEMBL813077 0.79 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL29188855 0.78 CA1 (0.64) CA1CA2MMP1MMP2MMP9
SCHEMBL15880861 0.77 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL12353346 0.77 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL812692 0.77 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL28192865 0.77 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL422151 0.77 CA1 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL9176627 0.77 CA1 (0.62) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751445-A Preparation method of 6-ethynyl pyrazolo [1,5-a ] pyridine 江南大学 2025-04-04 CN claimed
CN-115417875-B Synthesis method of 5, 8-dimethoxy- [1,2,4] triazolo [1,5-C ] pyrimidine-2-amine 山东华升新材料有限公司 2024-05-31 CN claimed
CN-112724099-B (4-amino-5-imino-4, 5-dihydro-1, 3, 4-oxadiazol-2-yl) dinitromethane 中国工程物理研究院化工材料研究所 2022-08-19 CN claimed
CN-112724133-B Preparation method of 6-bromopyrazolo [1,5-a ] pyridine 湖南复瑞生物医药技术有限责任公司 2022-03-25 CN claimed
CN-112724099-A (4-amino-5-imino-4, 5-dihydro-1, 3, 4-oxadiazol-2-yl) dinitromethane 中国工程物理研究院化工材料研究所 2021-04-30 CN claimed
EP-3126338-B1 DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP Bayer Pharma AG (DE) 2019-09-04 EP claimed
US-9790189-B2 Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-17 US claimed
EP-3126338-A1 DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP Bayer Pharma Aktiengesellschaft (DE) 2017-02-08 EP claimed
US-20170015634-A1 DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-19 US claimed
WO-2015150273-A1 DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-08 WO claimed
EP-2254900-A1 CHEMICAL MODIFICATION OF PROTEINS ISIS Innovation Limited (GB) 2010-12-01 EP claimed
WO-2009103941-A1 CHEMICAL MODIFICATION OF PROTEINS ISIS INNOVATION LIMITED (GB) 2009-08-27 WO claimed
EP-1304326-A4 SINGLE-STEP PROCESS FOR PREPARING 7,16-DEOXY-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHYDROXI-6-ETHYL-3,5,9,11,13,15-HEXAMETHYLBICYCLE (11.2.1)HEXADECA-1(2)-EN-8-ONA AND OBTAINING A NEW FORM OF 9-DESOXO-9A-METHYL-9A-AZA-9A-HOMOERYTHROMYCIN A SILANES SA DE CV LAB (MX) 2004-06-16 EP claimed
EP-1304326-A1 SINGLE-STEP PROCESS FOR PREPARING 7,16-DEOXY-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHYDROXI-6-ETHYL-3,5,9,11,13,15-HEXAMETHYLBICYCLE (11.2.1)HEXADECA-1(2)-EN-8-ONA AND OBTAINING A NEW FORM OF 9-DESOXO-9A-METHYL-9A-AZA-9A-HOMOERYTHROMYCIN A Laboratorio Silanes, S.A. de C.V. (MX) 2003-04-23 EP claimed
WO-2002010144-A1 SINGLE-STEP PROCESS FOR PREPARING 7,16-DEOXY-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHYDROXI-6-ETHYL-3,5,9,11,13,15-HEXAMETHYLBICYCLE (11.2.1)HEXADECA-1(2)-EN-8-ONA AND OBTAINING A NEW FORM OF 9-DESOXO-9A-METHYL-9A-AZA-9A-HOMOERYTHROMYCIN A LABORATORIO SILANES, S.A. DE C.V. (MX) 2002-02-07 WO claimed
EP-0176806-A1 1,2,4-Benzothiadiazinoxide derivatives, method for their preparation and medicaments containing them GÖDECKE AKTIENGESELLSCHAFT (DE) 1986-04-09 EP claimed
JP-56039080-A None JP disclosed
JP-56128769-A None JP disclosed
US-3978052-A ANTIHISTAMINIC, ANTITUSSIVE, ANTIINFLAMMATORY, DIURETIC WARNER-LAMBERT COMPANY (US) 1976-08-31 US disclosed
US-3974286-A INSECTICIDES ELI LILLY AND COMPANY (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015634-A1 DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFONDIIMINE GROUP DHFR, DPYD, TYMP CA1 4649/4885CA2 4625/4885MMP1 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.